Jeil's anti-cancer drug business is doing well

Jeil will strategically partner with Kyowa Kirin and Taiho to introduce and sell original new drugs

Construction of pipelines such as Grasin, UFT, Ts-1, Neulasta, and Lonsurf, etc.

Onconic therapeutics, targeted anti-cancer drugs JPI-547

It is noteworthy that Jeil is investing in expanding the lineup of anticancer drugs and research and development in related fields.

 

Jeil, who entered his 33rd year of anti-cancer drug business, has a strategic relationship with Kyowa Kirin and Taiho in Japan and is making efforts to distribute original anti-cancer drugs.

 

When the new anti-cancer drugs were introduced in the late 1980s, Jeil established a separate anti-cancer sales and marketing team to strengthen its professional capabilities and make communication between doctors and salespeople a top priority.

 

The most likely anti-cancer drugs are Grasin300 PFS (Kyowa Kirin), Neulasta PFS(Kyowa Kirin), UFT(Taiho), Ts-1(Taiho), and Lonsurf (Taiho).

 

The first anti-cancer drug introduced by Jeil was UFT(Tegafur·Uracil), which was first released in Korea in 1989.

 

It is effective in relieving symptoms such as head and neck cancer, stomach cancer, rectal cancer, liver cancer, lung cancer, prostate cancer, uterine cervical cancer, and breast cancer, etc.

 

UFT has capsule formulations and granules, which are usually administered three to six capsules a day, and the granules are taken in two to three doses of 300 to 600 mg.

 

In 1993, Grasin300 PFS (Filgrastim) was released.

 

The drug, which is a granulocyte colony-stimulating factor (GCSF) preparation, has indications of neutrophilosis, bone marrow dysplasia, regenerative anemia, congenital and idiopathic neutrophilia (HIV) infections.

 

In 2004, the company launched a treatment called Ts-1(Gimeracil, Oteracil Potassium,Tegafur) for stomach, head and neck cancer, pancreatic cancer, and non-small cell lung cancer, providing a variety of treatment options for domestic patients.

 

In 2014, it released Neulasta (Pegfilgrastim), the second generation G-CSF and co-sold it in Korea with Kyowa Kirin.

 

Last year, Lonsurf (Tipiracil+Trifluridine) was introduced to provide new options for colon cancer treatment, and has continued its long sales experience in the domestic anticancer drug market.

 

Lonsurf passed DC of 50 hospitals nationwide, including Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, and Severance Hospital in the first year of its launch.

 

Based on UBIST, it ranks first in sales in the field of oral anticancer drugs newly approved in 2020, and is recognized for its efficacy.

 

Lonsurf is expanding its share of the colon cancer market using a specialised sales network.

 

Attention is also focusing on Onconic therapeutics, which was established last year to improve its position in the anti-cancer drug R&D field.

 

Bio company Onconic therapeutics is a subsidiary 100% invested by Jeil and is expected to grow as an organization focused on the development of immune and targeted anti-cancer drugs.

 

A year after its establishment, the company announced the results of Phase 1 for PARP (Poly ADP-ribose Polymerase) and JPI-547 at ASCO, drawing attention from Big Pharma.

 

Phase I of the clinical trial evaluated the medicinal efficacy, safety of JPI-547 in patients with terminal solid cancer, according to Lim Seok-ah, a professor of hemato-oncology at Seoul National University Hospital, announced at the poster session.

 

It is encouraging to identify the potential as a new treatment for ovarian cancer that does not respond to existing PARP treatments.

 

Based on the results of this Effects are expected in HRD and PARP inhibitor resistant patients, including BRCA.

 

"Based on the 30-year history of introducing anti-cancer drugs, we are continuously expanding our specialized sales network in related fields." said a representative of Jeil.

 

"We will strengthen the pipeline of new items and improve our long-term research and development capabilities in the anticancer drugs market through open collaboration with Onconic Therapheutics."